These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18198495)

  • 1. The effects of pharmaceutical excipients on drug disposition.
    Buggins TR; Dickinson PA; Taylor G
    Adv Drug Deliv Rev; 2007 Dec; 59(15):1482-503. PubMed ID: 18198495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters.
    Bittner B; Mountfield RJ
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):59-71. PubMed ID: 11865674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitigating Cocrystal Physical Stability Liabilities in Preclinical Formulations.
    Bhardwaj S; Lipert M; Bak A
    J Pharm Sci; 2017 Jan; 106(1):31-38. PubMed ID: 27665129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical Excipients and Drug Metabolism: A Mini-Review.
    Patel R; Barker J; ElShaer A
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclodextrins in Parenteral Formulations.
    Loftsson T
    J Pharm Sci; 2021 Feb; 110(2):654-664. PubMed ID: 33069709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes.
    Loftsson T; Brewster ME
    J Pharm Pharmacol; 2011 Sep; 63(9):1119-35. PubMed ID: 21827484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical comparison of intravenous melphalan pharmacokinetics administered in formulations containing either (SBE)7 m-β-cyclodextrin or a co-solvent system.
    Koltun M; Morizzi J; Katneni K; Charman SA; Shackleford DM; McIntosh MP
    Biopharm Drug Dispos; 2010 Nov; 31(8-9):450-4. PubMed ID: 20865695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of stability and skin permeation by sucrose stearate and cyclodextrins in progesterone nanoemulsions.
    Klang V; Matsko N; Zimmermann AM; Vojnikovic E; Valenta C
    Int J Pharm; 2010 Jun; 393(1-2):152-60. PubMed ID: 20434531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclodextrins as excipients in tablet formulations.
    Conceição J; Adeoye O; Cabral-Marques HM; Lobo JMS
    Drug Discov Today; 2018 Jun; 23(6):1274-1284. PubMed ID: 29689302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suitability of commonly used excipients for electrophysiological in-vitro safety pharmacology assessment of effects on hERG potassium current and on rabbit Purkinje fiber action potential.
    Himmel HM
    J Pharmacol Toxicol Methods; 2007; 56(2):145-58. PubMed ID: 17590357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of excipients on transporter mediated absorption.
    Goole J; Lindley DJ; Roth W; Carl SM; Amighi K; Kauffmann JM; Knipp GT
    Int J Pharm; 2010 Jun; 393(1-2):17-31. PubMed ID: 20417699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan.
    Rajpoot P; Bali V; Pathak K
    Int J Pharm; 2012 Apr; 426(1-2):219-230. PubMed ID: 22301424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients.
    Martin P; Giardiello M; McDonald TO; Rannard SP; Owen A
    Mol Pharm; 2013 Jul; 10(7):2739-48. PubMed ID: 23701529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of a statistical method to the absorption of a new model drug from micellar and lipid formulations--evaluation of qualitative excipient effects.
    Kuentz M; Wyttenbach N; Kuhlmann O
    Pharm Dev Technol; 2007; 12(3):275-83. PubMed ID: 17613891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effects of Pharmaceutical Excipients on Gastrointestinal Tract Metabolic Enzymes and Transporters-an Update.
    Zhang W; Li Y; Zou P; Wu M; Zhang Z; Zhang T
    AAPS J; 2016 Jul; 18(4):830-43. PubMed ID: 27184579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solubilizing excipients in oral and injectable formulations.
    Strickley RG
    Pharm Res; 2004 Feb; 21(2):201-30. PubMed ID: 15032302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and evaluation of ibuprofen-loaded microemulsion for improvement of oral bioavailability.
    Hu L; Yang J; Liu W; Li L
    Drug Deliv; 2011 Jan; 18(1):90-5. PubMed ID: 20942639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug.
    Mohsin K; Alamri R; Ahmad A; Raish M; Alanazi FK; Hussain MD
    Int J Nanomedicine; 2016; 11():2829-38. PubMed ID: 27366063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solubility of Cyclodextrins and Drug/Cyclodextrin Complexes.
    Saokham P; Muankaew C; Jansook P; Loftsson T
    Molecules; 2018 May; 23(5):. PubMed ID: 29751694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.